Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled trial of 120 binge-drinking MSM to 12 weeks of
naltrexone 50mg, to be taken in anticipation of heavy drinking. Ethnically and racially
diverse participants will be recruited using Respondent Driven Sampling as well as active
field recruitment. MSM will be seen weekly for alcohol-metabolite urine testing, study drug
dispensing, and brief counseling for alcohol use. Safety assessments and behavioral surveys
will be completed monthly.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Institutes of Health (NIH) San Francisco Department of Public Health